On the Biotechnology Frontier: Personalized Medicine, A Discussion with E.J. Brandreth - In 10 years, personalized treatment will become a significant part of the biotechnology sector. - BioPharm


On the Biotechnology Frontier: Personalized Medicine, A Discussion with E.J. Brandreth
In 10 years, personalized treatment will become a significant part of the biotechnology sector.

BioPharm International
Volume 20, Issue 10

Are there any shortfalls of production at small scale?

The only thing that doesn't become easier at small scale is certain aspects of compliance, such as batch records. If you were making Herceptin or Rituxan in a 12,000-L bioreactor, you would have a large batch record; it's the same size batch record if you're only making 12 L for a patient lot: the size of the bioreactor has come down, but you still have the same compliance issues.

How much protein does each batch or lot yield? How does this quantity relate to the dosage needed for the patient? Does the patient receive dosing over an extended period?

The process was identified as being sufficient to produce enough product to treat a patient for at least three years. Patients with indolent non Hodgkin's lymphoma are faced with eventual disease progression in most cases. FavId is designed to extend the time to progression for patients with follicular lymphoma, one of the most common types of lymphoma. Each patient receives six initial monthly subcutaneous injections of FavId along with four daily subcutaneous injections of Luekine (GM-CSF), a cytokine intended to enhance the immune system response to FavId. If the patient's disease is stable or in remission, then he or she moves into maintenance therapy and receives bi-monthly injections for one year and then quarterly injections until disease progression.

Is this type of production economically feasible? How does your cost of goods compare with those for mass-produced biologics?

It really is a completely different business model than mass-produced biologics, and until a few years ago, it was not economically feasible. Today, by using our proprietary processes including the use of baculovirus and insect cell cultures, we have rapid turnaround time for the product, and "time is money." Moreover, the availability of affordable disposable materials and equipment has helped to make this new approach to medicine practical and affordable.

How will personalized medicine affect patient care?

We have found that there is great variability within one type of cancer: there are many types of breast cancer, colon cancer, etc. This is because there is variability in the types of mutations leading to cancer; we need personalized therapy to address the specific tumor. It used to take too long to sequence the DNA and generate the protein. It was too expensive and time consuming.

We have completed over 300 lots for our Phase 3 trial; we have an impressive data base before going commercial. That's rare for the biotech industry, which often has only 5–10 lots at commercial scale when they apply for a license, because each lot is so expensive.

This means we're sitting on 300+ cell culture runs, purification runs, and aseptic fills. If you look at final product testing, which requires 10–20 tests, and multiply that by 300, there is a huge amount of quality control testing data available.

How long do you think you will get approval?

Assuming positive data from our ongoing registration trial, we anticipate approval in early 2009.

Is it challenging to get approval (of product or process) because your clinical trial patient numbers are so small per lot?

We have a process that is shown to be reproducible for the wide variety of patient tumors we receive. Our historical data should demonstrate a very robust and licensable product. The clinical data will speak for itself; a safe and effective product should get rapid approval. Once approved, we anticipate rapid market penetration.

How long do you think personalized medicine will become a routine, or even a central part of production and a business model in the industry?

The use of personalized treatments is already occurring and the use of personalized products is in its infancy, but I expect in 10 years we will see this as a significant sector of the biotech industry.

blog comments powered by Disqus



AbbVie/Shire Deal Officially Off
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Lilly to Close Manufacturing Facility in Puerto Rico
October 17, 2014
BioReliance Introduces New Predictive Assays
October 17, 2014
Author Guidelines
Source: BioPharm International,
Click here